makri dou 2009
TRANSCRIPT
-
7/22/2019 Makri Dou 2009
1/96
...:...
:
:: ..
:, ,
: .
22000099
1
-
7/22/2019 Makri Dou 2009
2/96
2009,
,
.
.
, , . ,
.
, .
,
.
.
.
.
( Sc, PhD)
,
.
2
-
7/22/2019 Makri Dou 2009
3/96
..................................................................................................... i
..... ii
.. v
1 : I
1.1 11.2 .... 21.2.1 ... 2
1.2.2
-... 31.2.3 . 41.2.4 ... 5
2: -
2.1 - 72.2 - 9
2.3 - u 10
3:
3.1 . 123.1.1 . 123.1.2 133.1.3 .. 13
3.1.4 143.2 .. 15
3
-
7/22/2019 Makri Dou 2009
4/96
3.2.1 .. 16
3.3 173.3.1 173.3.2 .. 183.3.3 213.3.4 21
4:
4.1 224.1.1 23
4.1.2 244.2 . 254.3 254.4 . 264.5 .. . 274.6 -. 284.7 . 284.8 .. 304.9 314.10
32
5:
5.1 .345.2 355.2.1 ..36
5.3 385.4 385.4.1 385.4.2 405.4.3 415.4.4 425.5 ; 45
4
-
7/22/2019 Makri Dou 2009
5/96
6:
6.1 466.1.1 476.2 50
52 .. 52 ... 53 . 56 74 .. 76
:
.. 80
. 86
5
-
7/22/2019 Makri Dou 2009
6/96
.
( , , ,
, ).
. ,
, .
(ventrogluteal).
,
.
.
,
,
, 81,5%
, 4,5%
0,5% .
.
6
-
7/22/2019 Makri Dou 2009
7/96
1
1.1
Yaws kala-
azar 1920
(Wyatt HV ,1984).
500 .. , 1880
(Howard-
Jones,1971). ,
(Stokes,Beerman & Ingraham, 1944).
Zelman (1961),
,
. 1957
,
. (Henderson, 1963,1966, 1970, 1972).
'60,
.
'60,
(Dison, 1967 Pitel & Wemett, 1964
Wempe, 1961).
7
-
7/22/2019 Makri Dou 2009
8/96
1.2
1.2.1
(. 2003).
:
1.1
,
( ) . ,
.
: , ,, .
8
-
7/22/2019 Makri Dou 2009
9/96
1.2.2 -
.
(. 2003)
:
- :
.
.
.
, ..
- .
:
,
.
,
(C.P.K) (L.D.H).
,
, ,
, .
, , ,
2.
9
-
7/22/2019 Makri Dou 2009
10/96
,
,
.
1.2-1.3
1.2.3
.
, .
, . (.
2003)
:
- Test .- test, .. mantoux
..
10
-
7/22/2019 Makri Dou 2009
11/96
1.4
2
. ,
, .
. 10-15
. .
1.2.4
.
2 .
.
. 1-5cc
, , , . ,
45 ,
. (. 2003)
:.
.
.
11
-
7/22/2019 Makri Dou 2009
12/96
2
1.4
12
-
7/22/2019 Makri Dou 2009
13/96
2
2.1.
: (1) ,
(2)
(, ,
) .
,
. ,
.
.
. ,
, ,
45 .
(Gichard L. D. et al. 2006).
13
-
7/22/2019 Makri Dou 2009
14/96
..
.
.
.
. .. .
, ..
.
. (Gichard L. D. et al. 2006).
.
. .
. .
2.1 (Gichard L. D. et al. 2006).
,.
. .
.
,.
.
.
,.
.
14
-
7/22/2019 Makri Dou 2009
15/96
2.2.
, ,
. ,
. : , ,
.(Gichard L. D. et al. 2006).
2.2:
: ,
, ,
,
. ,
, .
,
.
15
-
7/22/2019 Makri Dou 2009
16/96
, .
.
, . (Gichard L. D. et al. 2006).
2.3.
, ,
. :
, , .
,
9 ,
9
9 .
,
2.2 (Gichard L. D. et al. 2006).
2.3:
16
-
7/22/2019 Makri Dou 2009
17/96
2.2 (Gichard L. D. et al. 2006).
&
.
.
17
-
7/22/2019 Makri Dou 2009
18/96
-
7/22/2019 Makri Dou 2009
19/96
3.1.2
(Ipp et al.,1989). ACIP
.
,
..
(Bergeson et al,.1982) .
. 3 5
(Beyea & Nicoll, 1995).
. 25-38
2ml.
3.1.3
(Beecroft & Redick 1990, Hahn 1990, Covington & Trattler 1997).
.
2 , .
.
.
( .,2003).
2-5ml 38
.
. H
,
(Zelman,1961).
19
-
7/22/2019 Makri Dou 2009
20/96
(Kozier et al.,1993). ... 12%
(Farley,1986).
3.2:
3.1.4
,
.
,
(Bolander 1994, Rosdah 1995).
.
(Bolander,1994).
20
-
7/22/2019 Makri Dou 2009
21/96
3.3:
3.2
.
.
.
.
.
.
. 22-27
, 18-25 .
. 0,5ml
.(Zenk,1982,1993)
.
.(Hahn,1990,McConnell,1982)
21
-
7/22/2019 Makri Dou 2009
22/96
,
,.
3.2.1
Nisbet A. (2006)
100 .12
35 ,
, 26 25 .,
. 43
35 ., 72 25 .
.
.
,
, ,
. ,
.
,
. ,
22
-
7/22/2019 Makri Dou 2009
23/96
3.1
,
,
(., 2003 )
3.3
3.3.1
. ,
. ,
.
.(Haber et al. 2000, Hochstetter1954,1955,1956)
, (Hanson,1963).
.
23
-
7/22/2019 Makri Dou 2009
24/96
.
(Kruszewski et al,1979).
. 5-8cm
(Berger & Williams,1992, Murphy,1991).
3.3.2
.. ,
.
Jablecki (2000) ,
. , 2 3 .
,
.
(Light & Perl, 1993). Jablecki (2000)
. Barnhill, Holbert, Jackson & Erickson (1996)
10
, 93
.
.
.
90
.(Belanger-Annable 1985, Dickerson 1992, Gros-wasser 1997, McConnell 1982)
.
72-90 (Katsma D. & Katsma R.,2000). , 72-
24
-
7/22/2019 Makri Dou 2009
25/96
90 .
.
. .
. (Workman,1999)
3.4:
, 10 ml
(Zelman,1961).
.
10
(-). (Hahn 1990, Stokes et al. 1944, Zelman 1961).
25
-
7/22/2019 Makri Dou 2009
26/96
-:
.
(Beyea & Nicholl 1995)
, (Keen 1986).
( 3.4)
1 2cm.
,
. ,
,
, .
.
10 .
, .
.
(Beyea & Nicholl 1995).
26
-
7/22/2019 Makri Dou 2009
27/96
3.3.3
E.
.
,
,
(Beyea & Nicholl 1995). ,
( )
(MacGabhann 1998, Quartermaine & Taylor 1995)
- ,
. Quartermaine Taylor (1995)
- , MacGabhann (1998)
.
(Chaplin et al. 1985).
. ,
,
,
.
3.3.4.
2-4 (Roberts,1975).
.
.
27
-
7/22/2019 Makri Dou 2009
28/96
4
.
, . : ,
, , , ,
, ,
.O
. ,
. (Small S.P. 2004)
4.1
.
(Workman B. 1999).
4.1,4.2: 10 x 6
28
-
7/22/2019 Makri Dou 2009
29/96
4.1.1
.
, , .
.
.
. , ,
.
.
, ,
(Wounds 2003).
4.3:
.
29
-
7/22/2019 Makri Dou 2009
30/96
4.1.2
.
.
.
.
, ,
.
.
(Wounds 2003).
4.4:
30
-
7/22/2019 Makri Dou 2009
31/96
4.2
.. ,
(Chung J. et al. 2001).
.
,
.
Torrance (1989) :
.
.
.
.
.
.
4.3
,
(Pollilio & Kiley 1997). ,
.
31
-
7/22/2019 Makri Dou 2009
32/96
4.4
,
, .
.
.
, .
,
,
(Small S.P. 2004).
, , (
).
: , , ,
.
, o. ,
(Small S.P. 2004).
.
.
.
.(Pandian et al. 2006)
32
-
7/22/2019 Makri Dou 2009
33/96
4.5
.
. .
,
(Cheng J. & Abdi S. 2007).
. : )
, ) )
(Wounds 2003).
4.5:
33
-
7/22/2019 Makri Dou 2009
34/96
4.6 -
.
.
.
.
.
(Wounds 2003).
4.7
C (HBV,HCV), HIV, Ebola Lassa (Simonsen L. et al.1999).
,
, , , ,
, .
.
. ,
o
,
, .
34
-
7/22/2019 Makri Dou 2009
35/96
,
, , , , ,
, (Kermode M. 2004).
. ,
.
,
.
.
,
.
,
.
, ,
.
, ,
.
,
.,
(Simonsen L. et al.
1999).
35
-
7/22/2019 Makri Dou 2009
36/96
4.8
:
,
( ).
,
,
. Kozier et al. (1993)
,
. ,
5-7.5
(DuGas & Knor 1995, Perry &
Potter 1998).
:
(Greenblatt & Allen
1978) . ,
, ,
,
.,
.
2 mL .
( 2 mL) ,
. (
) ,
(0.5-2 mL ),
(Cocoman A. & Murray J. 2008).
36
-
7/22/2019 Makri Dou 2009
37/96
:
,
(Zelman 1961).
,
(Muller-Vahl 1985)
. Winslow (1996)
.
(Farley et al. 1986)
. , (Michaels & Poole
1970),
(Zelman 1961), ,
.
:
,
.
-
. ,
(Cocoman A. & Murray J. 2008).
4.9
.
,
.
. , ,
,
(Cheng J. & Abdi S. 2007).
37
-
7/22/2019 Makri Dou 2009
38/96
,
(Beyea & Nicholl 1995).
- (Burden 1994).
, ,
.
- (-track)
(Beyea & Nicholl
1995).
(Springhouse Corporation 1993).
,
(Pollilio Kiley 1997).
1) ,
.
2)
, , .
38
-
7/22/2019 Makri Dou 2009
39/96
3) ,
(
).
4)
.
5) ,
.
6)
, .
7) - (-track).
8) .
9) ,
90 ,
.
10) : 1ml
.
11)
.
12) ,
. (Workman B. 1999)
39
-
7/22/2019 Makri Dou 2009
40/96
5
5.1
12 .
5%
, .
0.9
8.5 1.5 (Lala K. &
Lala M. 2003)
26.294 Boston
Collaborative Drug Surveillance Program, (
,) 46% .
80%
: G , ,
, , colistimethate sodium,
, , , , ,
(Greenblatt DJ & Allen MD 1978).
, (WHO 1998).
o ,
-
.
0.9 8.5
1.5 . , ,
40
-
7/22/2019 Makri Dou 2009
41/96
, ,
25% 96%.
.
1997
10 .
500
: 20
120 .
65
. (Simonsen L. et al.1999).
,
, , IV .
5.2
1987 -1998 .
19
. 14 50
. , 20
> 31
.
, 50
. ,
31 >90
. (Simonsen L. et al.1999).
.
41
-
7/22/2019 Makri Dou 2009
42/96
5% , 95%
.
20% 80%
.
30
.(Simonsen L. et al.1999).
5.2.1
,
..
,
. ,
,
, (Kermode . 2004).
1) .
2) .
3) .
4) ,
(
).
5)
.
42
-
7/22/2019 Makri Dou 2009
43/96
6)
.
7) .
8) , .
9)
.
10) .
11)
.
12) ,
.
13)
.
14)
.
15) .
16) .
17) .
43
-
7/22/2019 Makri Dou 2009
44/96
5.3
66 , 70
.
, 82
.
96
, .
85 99
. ,
: .
, ,
(Simonsen L. et al.1999).
5.4
5.4.1
,
. ,
.
66
, 1990 2003 36 (55%)
,29 (44%) (1%) . 57 (86%),
44
-
7/22/2019 Makri Dou 2009
45/96
. ,
(Pandian et al. 2006).
:
, 41 (62%) , 23 (35%) , 7 (11%) , 34
(52%) , 22 (33%).
59 (89%) 7 (11%) .
8.5 22.9 .
(p < 0.02) (p